<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-18T23:16:08Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/18100" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/18100</identifier><datestamp>2026-10-18T20:56:22Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>The Relationship Between Chemotherapy Related Neutropenia and Survival in Ovarian Cancer</dc:title><dc:creator>SANCİ, Muzaffer</dc:creator><dc:creator>Can, Behzat</dc:creator><dc:creator>ATAG, Elif</dc:creator><dc:creator>AKAGUNDUZ, Baran</dc:creator><dc:creator>SEMİZ, Huseyin Salih</dc:creator><dc:subject>Tıbbi Araştırmalar Deneysel</dc:subject><dc:subject>Transplantasyon</dc:subject><dc:subject>Onkoloji</dc:subject><dc:description>Objectives: Due to limited data in the literature, we aimed to determine the relationship between the development of chemotherapy-induced neutropenia and survival in patients with ovarian cancer who underwent frontline cytoreduc- tive surgery and received adjuvant chemotherapy. Methods: In this study, laboratory parameters in the hospital database were collected retrospectively. The rates of pa- tients who developed neutropenia due to chemotherapy and the relationship between neutropenia and survival were analyzed using appropriate statistical methods. Results: A total of 82 patients were included in the study. The median age was 53.3 years. Median follow-up time was 61,6 months. Median chemotherapy cycles were 6. Disease recurrence developed in 22 (26.8%) patients and 12 pa- tients (14.6%) were died during the follow-up period. Any degree of neutropenia developed in a total of 63 (76.8%) pa- tients during the entire chemotherapy period. There were no grade 4 neutropenia. No correlation was found between the development of neutropenia and disease free survival or overall survial. Conclusion: There are conflicting data in the literature regarding the relationship between chemotherapy-induced neutropenia and survival in patients with ovarian cancer who are receiving adjuvant chemotherapy. In our study, no relationship was found between the development of neutropenia and survival.</dc:description><dc:date>2023</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/18100</dc:identifier><dc:identifier>https://doi.org/10.14744/ejmi.2023.76099</dc:identifier><dc:language>en</dc:language><dc:relation>Eurasian Journal of Medical Investigation</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/18100</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>